anecortave acetate

Identification

Name
anecortave acetate
Accession Number
DB05288
Type
Small Molecule
Groups
Investigational
Description

Anecortave acetate (Retaane) is an analog of cortisol acetate; among the modifications to the steroid are the removal of the 11ß hydroxyl OH group and an addition of a 21-acetate group. As a result of these modifications, anecortave acetate lacks the typical antiinflammatory and immunosuppressive properties of glucocorticoids.Alcon Inc. is developing and marketing Retaane.

Structure
Thumb
Synonyms
Not Available
External IDs
AL 3789 / AL-3789
International/Other Brands
Retaane
Categories
UNII
Y0PC411K4T
CAS number
Not Available
Weight
Average: 386.4813
Monoisotopic: 386.20932407
Chemical Formula
C23H30O5
InChI Key
YUWPMEXLKGOSBF-GACAOOTBSA-N
InChI
InChI=1S/C23H30O5/c1-14(24)28-13-20(26)23(27)11-8-19-17-5-4-15-12-16(25)6-9-21(15,2)18(17)7-10-22(19,23)3/h7,12,17,19,27H,4-6,8-11,13H2,1-3H3/t17-,19+,21+,22+,23+/m1/s1
IUPAC Name
2-[(2S,10S,11S,14R,15S)-14-hydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-1(17),6-dien-14-yl]-2-oxoethyl acetate
SMILES
[H][[email protected]@]12CC[[email protected]](O)(C(=O)COC(C)=O)[[email protected]@]1(C)CC=C1[[email protected]@]2([H])CCC2=CC(=O)CC[[email protected]]12C

Pharmacology

Indication

Investigated for use/treatment in glaucoma and macular degeneration.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

Anecortave acetate functions as an antiangiogenic agent, inhibiting blood vessel growth by decreasing extracellular protease expression and inhibiting endothelial cell migration. Its angiostatic activity does not seem to be mediated through any of the commonly known pharmacological receptors. (Ophthalmology 2004;111:2316-7) RETAANE blocks signals from multiple growth factors because it acts downstream and independent of the initiating angiogenic stimuli and inhibits angiogenesis subsequent to the angiogenic stimulation.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when anecortave acetate is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with anecortave acetate.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with anecortave acetate.Approved, Experimental, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with anecortave acetate.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with anecortave acetate.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with anecortave acetate.Approved, Withdrawn
Aldesleukinanecortave acetate may decrease the antineoplastic activities of Aldesleukin.Approved
AlmasilateThe bioavailability of anecortave acetate can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with anecortave acetate.Experimental
AloglutamolThe bioavailability of anecortave acetate can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with anecortave acetate.Experimental
AluminiumThe bioavailability of anecortave acetate can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of anecortave acetate can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of anecortave acetate can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of anecortave acetate can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with anecortave acetate.Approved
AmiodaroneThe serum concentration of anecortave acetate can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin Banecortave acetate may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with anecortave acetate.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with anecortave acetate.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with anecortave acetate.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with anecortave acetate.Approved, Investigational
AprepitantThe serum concentration of anecortave acetate can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of anecortave acetate can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of anecortave acetate.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with anecortave acetate.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with anecortave acetate.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with anecortave acetate.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when anecortave acetate is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with anecortave acetate.Experimental
Bendroflumethiazideanecortave acetate may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with anecortave acetate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with anecortave acetate.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with anecortave acetate.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with anecortave acetate.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with anecortave acetate.Experimental
Bismuth SubcitrateThe bioavailability of anecortave acetate can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of anecortave acetate can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of anecortave acetate can be increased when it is combined with Boceprevir.Approved, Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with anecortave acetate.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with anecortave acetate.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with anecortave acetate.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with anecortave acetate.Experimental
Bumetanideanecortave acetate may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with anecortave acetate.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of anecortave acetate can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of anecortave acetate can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideanecortave acetate may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe serum concentration of anecortave acetate can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with anecortave acetate.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with anecortave acetate.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with anecortave acetate.Approved, Investigational
Ceritinibanecortave acetate may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with anecortave acetate.Approved, Vet Approved
Chlorothiazideanecortave acetate may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of anecortave acetate can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
Chlorthalidoneanecortave acetate may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of anecortave acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with anecortave acetate.Approved
CinoxacinThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Cinoxacin.Approved, Investigational, Withdrawn
ClarithromycinThe serum concentration of anecortave acetate can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with anecortave acetate.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when anecortave acetate is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CobicistatThe serum concentration of anecortave acetate can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of anecortave acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of anecortave acetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of anecortave acetate can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with anecortave acetate.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when anecortave acetate is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with anecortave acetate.Investigational
Cyclopenthiazideanecortave acetate may increase the hypokalemic activities of Cyclopenthiazide.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with anecortave acetate.Investigational
DaidzeinThe serum concentration of anecortave acetate can be increased when it is combined with Daidzein.Experimental
Danazolanecortave acetate may increase the fluid retaining activities of Danazol.Approved
DarunavirThe serum concentration of anecortave acetate can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with anecortave acetate.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with anecortave acetate.Approved, Vet Approved
DienestrolThe serum concentration of anecortave acetate can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of anecortave acetate can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with anecortave acetate.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with anecortave acetate.Approved
Dihydrotestosteroneanecortave acetate may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DistigmineThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with anecortave acetate.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with anecortave acetate.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with anecortave acetate.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of anecortave acetate can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of anecortave acetate can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with anecortave acetate.Approved
EquolThe serum concentration of anecortave acetate can be increased when it is combined with Equol.Investigational
EstradiolThe serum concentration of anecortave acetate can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of anecortave acetate can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of anecortave acetate can be increased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of anecortave acetate can be increased when it is combined with Estrone.Approved
Etacrynic acidanecortave acetate may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with anecortave acetate.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with anecortave acetate.Experimental
Ethinyl EstradiolThe serum concentration of anecortave acetate can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with anecortave acetate.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with anecortave acetate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with anecortave acetate.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with anecortave acetate.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with anecortave acetate.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with anecortave acetate.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with anecortave acetate.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with anecortave acetate.Approved
FenthionThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with anecortave acetate.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with anecortave acetate.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with anecortave acetate.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with anecortave acetate.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with anecortave acetate.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with anecortave acetate.Experimental
Fluoxymesteroneanecortave acetate may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with anecortave acetate.Approved, Investigational
FosaprepitantThe serum concentration of anecortave acetate can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of anecortave acetate can be decreased when it is combined with Fosphenytoin.Approved
Furosemideanecortave acetate may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when anecortave acetate is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of anecortave acetate can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when anecortave acetate is combined with GI-5005.Investigational
GLPG-0492anecortave acetate may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with anecortave acetate.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with anecortave acetate.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with anecortave acetate.Experimental
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when anecortave acetate is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HexestrolThe serum concentration of anecortave acetate can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with anecortave acetate.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with anecortave acetate.Approved, Investigational
Hydrochlorothiazideanecortave acetate may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
Hydroflumethiazideanecortave acetate may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of anecortave acetate can be decreased when combined with Hydrotalcite.Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with anecortave acetate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with anecortave acetate.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with anecortave acetate.Approved
IdelalisibThe serum concentration of anecortave acetate can be increased when it is combined with Idelalisib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with anecortave acetate.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of anecortave acetate.Approved
Indapamideanecortave acetate may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of anecortave acetate can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with anecortave acetate.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with anecortave acetate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with anecortave acetate.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when anecortave acetate is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when anecortave acetate is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Ipidacrine.Experimental
IsoflurophateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with anecortave acetate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with anecortave acetate.Withdrawn
ItraconazoleThe serum concentration of anecortave acetate can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with anecortave acetate.Experimental
KetoconazoleThe serum concentration of anecortave acetate can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with anecortave acetate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with anecortave acetate.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with anecortave acetate.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with anecortave acetate.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with anecortave acetate.Experimental
LopinavirThe serum concentration of anecortave acetate can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with anecortave acetate.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with anecortave acetate.Approved, Investigational
LumacaftorThe serum concentration of anecortave acetate can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with anecortave acetate.Approved, Investigational
MagaldrateThe bioavailability of anecortave acetate can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe bioavailability of anecortave acetate can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of anecortave acetate can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of anecortave acetate can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with anecortave acetate.Approved
Magnesium silicateThe bioavailability of anecortave acetate can be decreased when combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe bioavailability of anecortave acetate can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with anecortave acetate.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with anecortave acetate.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with anecortave acetate.Approved
MefloquineThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with anecortave acetate.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with anecortave acetate.Approved
Mesteroloneanecortave acetate may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of anecortave acetate can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with anecortave acetate.Investigational, Withdrawn
MethallenestrilThe serum concentration of anecortave acetate can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Methanesulfonyl Fluoride.Investigational
Methyclothiazideanecortave acetate may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with anecortave acetate.Approved, Vet Approved
Methyltestosteroneanecortave acetate may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Metoclopramide.Approved, Investigational
Metolazoneanecortave acetate may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of anecortave acetate can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Minaprine.Approved
MitotaneThe serum concentration of anecortave acetate can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of anecortave acetate.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with anecortave acetate.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with anecortave acetate.Experimental
MoxestrolThe serum concentration of anecortave acetate can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with anecortave acetate.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with anecortave acetate.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with anecortave acetate.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with anecortave acetate.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with anecortave acetate.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Nalidixic Acid.Approved, Investigational
Nandroloneanecortave acetate may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
Nandrolone decanoateanecortave acetate may increase the fluid retaining activities of Nandrolone decanoate.Approved, Illicit
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with anecortave acetate.Approved, Vet Approved
NefazodoneThe serum concentration of anecortave acetate can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of anecortave acetate can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with anecortave acetate.Approved
NevirapineThe serum concentration of anecortave acetate can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with anecortave acetate.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with anecortave acetate.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with anecortave acetate.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with anecortave acetate.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Norfloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with anecortave acetate.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with anecortave acetate.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with anecortave acetate.Vet Approved
Oxandroloneanecortave acetate may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with anecortave acetate.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Oxolinic acid.Experimental
Oxymetholoneanecortave acetate may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with anecortave acetate.Approved, Withdrawn
ParaoxonThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with anecortave acetate.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with anecortave acetate.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of anecortave acetate can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of anecortave acetate can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with anecortave acetate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with anecortave acetate.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with anecortave acetate.Approved, Investigational
PhenytoinThe serum concentration of anecortave acetate can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with anecortave acetate.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Pipemidic acid.Experimental
Piretanideanecortave acetate may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with anecortave acetate.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with anecortave acetate.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with anecortave acetate.Experimental
Polyestradiol phosphateThe serum concentration of anecortave acetate can be increased when it is combined with Polyestradiol phosphate.Approved
Polythiazideanecortave acetate may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of anecortave acetate can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with anecortave acetate.Experimental, Investigational
PrimidoneThe serum concentration of anecortave acetate can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with anecortave acetate.Experimental
PromestrieneThe serum concentration of anecortave acetate can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with anecortave acetate.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with anecortave acetate.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with anecortave acetate.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with anecortave acetate.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of anecortave acetate can be increased when it is combined with Quinestrol.Approved
Quinethazoneanecortave acetate may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Rabies virus inactivated antigen, A.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of anecortave acetate.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with anecortave acetate.Approved, Experimental, Investigational
RifabutinThe serum concentration of anecortave acetate can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of anecortave acetate can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of anecortave acetate can be decreased when it is combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Rindopepimut.Investigational
RivastigmineThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with anecortave acetate.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with anecortave acetate.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with anecortave acetate.Approved, Vet Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with anecortave acetate.Approved
SaquinavirThe serum concentration of anecortave acetate can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of anecortave acetate can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with anecortave acetate.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with anecortave acetate.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with anecortave acetate.Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Sitafloxacin.Experimental, Investigational
Sodium bicarbonateThe bioavailability of anecortave acetate can be decreased when combined with Sodium bicarbonate.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when anecortave acetate is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with anecortave acetate.Investigational
St. John's WortThe serum concentration of anecortave acetate can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
Stanozololanecortave acetate may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of anecortave acetate can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with anecortave acetate.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with anecortave acetate.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with anecortave acetate.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with anecortave acetate.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of anecortave acetate can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of anecortave acetate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Tacrine.Investigational, Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with anecortave acetate.Investigational
TecemotideThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with anecortave acetate.Approved, Withdrawn
TelithromycinThe serum concentration of anecortave acetate can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with anecortave acetate.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with anecortave acetate.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with anecortave acetate.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with anecortave acetate.Approved
Testosteroneanecortave acetate may increase the fluid retaining activities of Testosterone.Approved, Investigational
Testosterone Propionateanecortave acetate may increase the fluid retaining activities of Testosterone Propionate.Approved, Vet Approved
TG4010The risk or severity of adverse effects can be increased when anecortave acetate is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with anecortave acetate.Approved
TiboloneThe serum concentration of anecortave acetate can be increased when it is combined with Tibolone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with anecortave acetate.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with anecortave acetate.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with anecortave acetate.Approved
Torasemideanecortave acetate may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with anecortave acetate.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with anecortave acetate.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Trichlorfon.Vet Approved
Trichlormethiazideanecortave acetate may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with anecortave acetate.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with anecortave acetate.Approved
TromethamineThe bioavailability of anecortave acetate can be decreased when combined with Tromethamine.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with anecortave acetate.Investigational, Withdrawn
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when anecortave acetate is combined with Zoster vaccine.Approved
VoriconazoleThe serum concentration of anecortave acetate can be increased when it is combined with Voriconazole.Approved, Investigational
Warfarinanecortave acetate may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with anecortave acetate.Approved, Investigational
ZeranolThe serum concentration of anecortave acetate can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with anecortave acetate.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with anecortave acetate.Withdrawn
Food Interactions
Not Available

References

General References
  1. Augustin A: Anecortave acetate in the treatment of age-related macular degeneration. Clin Interv Aging. 2006;1(3):237-46. [PubMed:18046876]
External Links
PubChem Compound
111332
PubChem Substance
175426966
ChemSpider
99892
ChEBI
31215
ChEMBL
CHEMBL2106613
Wikipedia
Anecortave

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedPreventionDiffuse posterior uveitis / Glaucoma1
1CompletedTreatmentMaculopathies, Age-Related1
1, 2CompletedTreatmentChronic Central Serous Chorioretinopathy1
2CompletedTreatmentAMD2
2CompletedTreatmentAge-Related Macular Degenerations / Subfoveal Neovascularization1
2CompletedTreatmentCoat's Disease1
2CompletedTreatmentEye Diseases1
2CompletedTreatmentIdiopathic Perifoveal Telangiectasia1
2CompletedTreatmentOpen-angle Glaucoma (OAG)2
2TerminatedTreatmentCentral Retinal Vein Occlusion (CRVO) / Chronic Inflammation / Infectious Diseases / Severe Diabetic Retinopathy1
2TerminatedTreatmentEye Injuries1
2WithdrawnTreatmentRetinal Vein Occlusions(RVO)1
2, 3CompletedTreatmentOpen-angle Glaucoma (OAG) / Oular Hypertension1
2, 3WithdrawnTreatmentOpen-angle Glaucoma (OAG)1
3CompletedTreatmentMacular Degeneration / Maculopathies, Age-Related2
3TerminatedPreventionAMD2
3TerminatedTreatmentDry AMD1
3TerminatedTreatmentMacular Degeneration1
Not AvailableNo Longer AvailableNot AvailableMacular Degeneration1
Not AvailableTerminatedTreatmentIntraocular Pressure / Transplanted1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0113 mg/mLALOGPS
logP3.33ALOGPS
logP2.62ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)12.61ChemAxon
pKa (Strongest Basic)-3.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area80.67 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity105.81 m3·mol-1ChemAxon
Polarizability42.44 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.983
Blood Brain Barrier+0.9851
Caco-2 permeable-0.6606
P-glycoprotein substrateSubstrate0.7382
P-glycoprotein inhibitor IInhibitor0.7341
P-glycoprotein inhibitor IIInhibitor0.5925
Renal organic cation transporterNon-inhibitor0.7452
CYP450 2C9 substrateNon-substrate0.8551
CYP450 2D6 substrateNon-substrate0.9294
CYP450 3A4 substrateSubstrate0.7841
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9556
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8588
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9246
Ames testNon AMES toxic0.9409
CarcinogenicityNon-carcinogens0.9551
BiodegradationNot ready biodegradable0.9354
Rat acute toxicity2.1280 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9599
hERG inhibition (predictor II)Non-inhibitor0.6638
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Pregnane steroids
Direct Parent
Gluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
20-oxosteroids / 3-oxosteroids / 17-hydroxysteroids / Cyclohexenones / Alpha-acyloxy ketones / Tertiary alcohols / Alpha-hydroxy ketones / Cyclic alcohols and derivatives / Carboxylic acid esters / Monocarboxylic acids and derivatives
show 2 more
Substituents
Progestogin-skeleton / 20-oxosteroid / 3-oxosteroid / 17-hydroxysteroid / Oxosteroid / Hydroxysteroid / Cyclohexenone / Alpha-acyloxy ketone / Alpha-hydroxy ketone / Tertiary alcohol
show 13 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
Not Available

Drug created on November 18, 2007 11:23 / Updated on December 01, 2017 15:35